Skip to main content
Publications
Paller AS, Yosipovitch G, Weidinger S, DiBenedetti D, Whalley D, Gadkari A, Guillemin I, Zhang H, Eckert L, Chao J, Bansal A, Chuang CC, Delevry D. Development, psychometric validation and responder definition of worst itch scale in children with severe atopic dermatitis. Dermatol Ther. 2022 Dec;12(12):2839-50. doi: 10.1007/s13555-022-00804-z
Simpson EL, de Bruin-Weller M, Eckert L, Whalley D, Guillemin I, Reaney M, Chen Z, Nelson L, Qin S, Bansal A, Gadkari A. Responder threshold for Patient-Oriented Eczema Measure (POEM) and Children's Dermatology Life Quality Index (CDLQI) in adolescents with atopic dermatitis. Dermatol Ther. 2019 Dec;9(4):799-805. doi: 10.1007/s13555-019-00333-2
Matharu M, Pascual J, Nisson Remahl I, Straube A, Lum A, Davar G, Odom D, Bennett L, Proctor C, Gutierrez L, Andrews E, Johannes C. Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe. Cephalalgia. 2017 Dec;37(14):1384-97. doi: 10.1177/0333102417724150
Bertelsen RJ, Rava M, Carsin AE, Accordini S, Benediktsdottir B, Dratva J, Franklin KA, Heinrich J, Holm M, Janson C, Johannessen A, Jarvis DL, Jogi R, Leynaert B, Norback D, Omenaas ER, Raherison C, Sanchez-Ramos JL, Schlunssen V, Sigsgaard T, Dharmage SC, Svanes C. Clinical markers of asthma and IgE assessed in parents before conception predict asthma and hayfever in the offspring. Clin Exp Allergy. 2017 May;47(5):627-38. doi: 10.1111/cea.12906
Matharu M, Pascual J, Nilsson Remahl L, Straube A, Johannes C, Odom D, Gutierrez L, Andrews E, Lum A. Interim analysis of the real-world utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine in an observational study in the European Union. Poster presented at the International Headache Conference; May 14, 2015. Valencia, Spain. [abstract] Cephalalgia. 2015; 35(6S):39.